The global Phase 3 CoMpass trial for bel-sar in early choroidal melanoma is advancing toward enrollment completion by mid-2026 under a Special Protocol Assessment. The study compares bel-sar to a sham control and aims to deliver 15-month primary endpoint topline data in the second half of 2027, potentially establishing the first frontline vision-preserving therapy in this indication.

In early May 2026, the company closed an oversubscribed underwritten public offering raising $299 million, netting approximately $280.8 million after expenses. Combined with $114.7 million in cash and marketable securities as of March 31, 2026, and after a $39 million share repurchase, Aura expects funding into the second half of 2028.

Effective April 30, 2026, Natalie Holles was appointed Chief Executive Officer, President and board member, succeeding founder Elisabet de los Pinos. This leadership change aligns with Aura’s focus on advancing late-stage clinical programs and strengthening corporate governance.

For Q1 2026, R&D expenses rose to $28.0 million from $23.3 million year-over-year driven by Phase 3 trial and manufacturing costs, while G&A expenses increased to $6.9 million from $5.7 million due to personnel and professional fees. Net loss widened to $33.7 million from $27.5 million in Q1 2025.